Anzalone Charles Lane, Glasgow Amy, Habermann Elizabeth, Grossard Brandon R, Van Gompel Jamie J, Carlson Matthew L
Department of Otorhinolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Surgical Outcomes Program, Mayo Clinic, Rochester, Minnesota, United States.
J Neurol Surg B Skull Base. 2019 Dec;80(6):547-554. doi: 10.1055/s-0038-1676376. Epub 2018 Dec 26.
Age, tumor size and location, overall health, and patient preference are primary considerations driving treatment decision-making for intracranial meningiomas. However, even for the same individual patient, treatment recommendations may vary between centers and providers. To study associations between geography, disease presentation, and management of intracranial meningioma in the United States. The population-based Surveillance, Epidemiology, and End Results(SEER) data were queried between 2004 and 2014 for cases of intracranial meningioma. A total of 65,808 patients with intracranial meningioma were identified. Univariate analyses demonstrated strong associations between geographic location, age, and size of tumor at presentation. The mean age for all registries was 64.2 years, with a range from 62.0 (Utah registry) to 66.6 (Detroit registry). The greatest proportion of small tumors (<1 cm) were identified in the Utah registry (13.9% of tumors), while the greatest proportion of large tumors (> 4cm) were noted in the Hawaii registry (30.7% of tumors). Multivariable analysis demonstrated that the impact of geography on treatment selection was just as important as other established variables. For example, the distribution in tumor size between New Mexico and Greater California registries is nearly identical; however, the odds ratio for surgery was 1.5 times greater for the New Mexico population. These data suggest that disease presentation and treatment are significantly influenced by regional referral patterns, provider or institutional treatment preferences, and regional availability of subspecialty expertise. Understanding such biases is important for patients, referring physicians, and treatment providers in an effort to provide balanced counseling and treatment.
年龄、肿瘤大小和位置、整体健康状况以及患者偏好是驱动颅内脑膜瘤治疗决策的主要考虑因素。然而,即使对于同一名患者,不同中心和医疗服务提供者给出的治疗建议也可能有所不同。 为研究美国颅内脑膜瘤的地理位置、疾病表现与治疗之间的关联。 基于人群的监测、流行病学和最终结果(SEER)数据库在2004年至2014年期间被查询,以获取颅内脑膜瘤病例。 共识别出65808例颅内脑膜瘤患者。单因素分析表明,地理位置、年龄与肿瘤初发时的大小之间存在密切关联。所有登记处的平均年龄为64.2岁,范围从62.0岁(犹他登记处)到66.6岁(底特律登记处)。在犹他登记处发现的小肿瘤(<1 cm)比例最高(占肿瘤的13.9%),而在夏威夷登记处发现的大肿瘤(>4 cm)比例最高(占肿瘤的30.7%)。多变量分析表明,地理位置对治疗选择的影响与其他既定变量同样重要。例如,新墨西哥州和大加利福尼亚登记处之间的肿瘤大小分布几乎相同;然而,新墨西哥州人群接受手术的优势比是大加利福尼亚州人群的1.5倍。 这些数据表明,疾病表现和治疗受到区域转诊模式、医疗服务提供者或机构的治疗偏好以及专科专业知识的区域可及性的显著影响。了解这些偏差对于患者、转诊医生和治疗提供者而言很重要,有助于提供平衡的咨询和治疗。